

TIER ONE ELIGIBILITY for EVUSHIELD

PILOT as of 1/24/22

Severe immunocompromising conditions:

Hematologic malignancies—acute leukemia, lymphoblastic lymphoma, NHL receiving anti-B or T cell depleting therapies or purine analog therapy as listed below

S/P allogeneic stem cell transplant within last 12 months or receiving immunosuppressive therapy for GvHD

S/P CART-T therapy within the last 12 months

S/P solid organ transplant within last 6 months or treated for rejection in last 3 months

HIV with CD4 count < 200

Highly immunosuppressive medications:

Anti-B or T cell depleting agents in the past 12 months (rituximab, ofatumumab, obinutuzumab, ocrelizumab, blinatumomab, alemtuzumab)

Purine analog in the past 6 months (cladribine, clofarabine, nelarabine, fludarabine, pentostatin, mercaptopurine)

Sphingosine 1-phosphate modulators (fingolimod, ozanimod, siponimod)

Mycophenolate mofetil (MMF) in the past 6 months for patients with severe ILD